Salem Radio Network News Sunday, August 1, 2021

Health

EMA analyses J&J COVID-19 vaccine data for cases of rare nerve disorder

ZURICH (Reuters) – The European Medicines Agency (EMA) on Tuesday said it is analysing Johnson & Johnson data on rare cases of a nerve disorder reported in patients who got the company’s COVID-19 vaccine after the United States placed a warning on the vaccine.

“As part of the review…EMA’s safety committee (PRAC) is analysing data provided by the marketing authorisation holder on cases of Guillain-Barre syndrome (GBS) reported following vaccination,” the regulator said in a statement to Reuters. “PRAC has requested (Johnson & Johnson) to provide further detailed data.”

The scrutiny comes as the U.S. Food and Drug Administration on Monday added a warning for Guillain-Barre to the fact sheet for J&J’s shot and as the EMA four days ago included a warning for AstraZeneca’s COVID-19 shot, to raise awareness among healthcare professionals and people getting the vaccine to be on alert for potential side effects.

(Reporting by John Miller, editing by Louise Heavens)

Previous
Next

Editorial Cartoons

View More »

Steve Breen
Wed, Jul 21, 2021

X CLOSE